The most common reason for menopause is the natural decline in a female's reproductive hormones. However, menopause can also result from the following situations:
Oophorectomy: This surgery, which removes a woman's ovaries, causes immediate menopause. Symptoms and signs of menopause in this situation can be severe, as the hormonal changes happen abruptly.
Chemotherapy: Cancer treatments like chemotherapy can induce menopause quickly, causing symptoms to appear shortly after or even during treatment.
Ovarian Insufficiency: Also called premature ovarian failure, this condition is essentially premature menopause. It happens when a woman's ovaries quit functioning before the age of 40 and can stem from genetic factors and disease. Only 1% of women suffer from premature menopause, but HRT can help protect the heart, brain, and bones.
If you're a woman going through menopause and find that you have become increasingly depressed, you're not alone. It's estimated that 15% of women experience depression to some degree while going through menopause. What many women don't know is that depression can start during perimenopause, or the years leading up to menopause.
Depression can be hard to diagnose, especially during perimenopause and menopause. However, if you notice the following signs, it might be time to speak with a physician:
Remember, if you're experiencing depression, you're not weak or broken - you're going through a very regular emotional experience. The good news is that with proper treatment from your doctor, depression isn't a death sentence. And with HRT and anti-aging treatment for women, depression could be the catalyst you need to enjoy a new lease on life.
Hot flashes - they're one of the most well-known symptoms of menopause. Hot flashes are intense, sudden feelings of heat across a woman's upper body. Some last second, while others last minutes, making them incredibly inconvenient and uncomfortable for most women.
Symptoms of hot flashes include:
Typically, hot flashes are caused by a lack of estrogen. Low estrogen levels negatively affect a woman's hypothalamus, the part of the brain that controls body temperature and appetite. Low estrogen levels cause the hypothalamus to incorrectly assume the body is too hot, dilating blood vessels to increase blood flow. Luckily, most women don't have to settle for the uncomfortable feelings that hot flashes cause. HRT treatments for women often stabilize hormones, lessening the effects of hot flashes and menopause in general.
Mood swings are common occurrences for most people - quick shifts from happy to angry and back again, triggered by a specific event. And while many people experience mood swings, they are particularly common for women going through menopause. That's because, during menopause, the female's hormones are often imbalanced. Hormone imbalances and mood swings go hand-in-hand, resulting in frequent mood changes and even symptoms like insomnia.
The rate of production of estrogen, a hormone that fluctuates during menopause, largely determines the rate of production the hormone serotonin, which regulates mood, causing mood swings.
Luckily, HRT and anti-aging treatments in Woodcliff Lake, NJ for women work wonders for mood swings by regulating hormone levels like estrogen. With normal hormone levels, women around the world are now learning that they don't have to settle for mood swings during menopause.
Staying fit and healthy is hard for anyone living in modern America. However, for women with hormone imbalances during perimenopause or menopause, weight gain is even more serious. Luckily, HRT treatments for women coupled with a physician-led diet can help keep weight in check. But which hormones need to be regulated?
Lowered sexual desire - three words most men and women hate to hear. Unfortunately, for many women in perimenopausal and menopausal states, it's just a reality of life. Thankfully, today, HRT and anti-aging treatments Woodcliff Lake, NJ can help women maintain a normal, healthy sex drive. But what causes low libido in women, especially as they get older?
The hormones responsible for low libido in women are progesterone, estrogen, and testosterone.
Progesterone production decreases during perimenopause, causing low sex drive in women. Lower progesterone production can also cause chronic fatigue, weight gain, and other symptoms. On the other hand, lower estrogen levels during menopause lead to vaginal dryness and even vaginal atrophy or loss of muscle tension.
Lastly, testosterone plays a role in lowered libido. And while testosterone is often grouped as a male hormone, it contributes to important health and regulatory functionality in women. A woman's testosterone serves to heighten sexual responses and enhances orgasms. When the ovaries are unable to produce sufficient levels of testosterone, it often results in a lowered sex drive.
Often uncomfortable and even painful, vaginal dryness is a serious problem for sexually active women. However, like hair loss in males, vaginal dryness is very common - almost 50% of women suffer from it during menopause.
Getting older is just a part of life, but that doesn't mean you have to settle for the side effects. HRT and anti-aging treatments for women correct vaginal dryness by re-balancing estrogen, progesterone, and testosterone. When supplemented with diet and healthy living, your vagina's secretions are normalized, causing discomfort to recede.
Uterine fibroids - they're perhaps the least-known symptom of menopause and hormone imbalances in women. That's because these growths on the uterus are often symptom-free. Unfortunately, these growths can be cancerous, presenting a danger for women as they age.
Many women will have fibroids at some point. Because they're symptomless, they're usually found during routine doctor exams. Some women only get one or two, while others may have large clusters of fibroids. Because fibroids are usually caused by hormone imbalances, hysterectomies have been used as a solution, forcing women into early menopause.
Advances in HRT and anti-aging medicine for women give females a safer, non-surgical option without having to experience menopause early. At Global Life Rejuvenation, our expert physicians will implement a customized HRT program to stabilize your hormones and reduce the risk of cancerous fibroid growth.
Endometriosis symptoms are much like the effects of PMS, and include pelvic pain, fatigue, cramping, and bloating. While doctors aren't entirely sure what causes this painful, uncomfortable condition, most agree that hormones - particularly xenoestrogens - play a factor.
Endometriosis symptoms are much like the effects of PMS and include pelvic pain, fatigue, cramping, and bloating. While doctors aren't entirely sure what causes this painful, uncomfortable condition, most agree that hormones - particularly xenoestrogens - play a factor.
Xenoestrogen is a hormone that is very similar to estrogen. Too much xenoestrogen is thought to stimulate endometrial tissue growth. HRT for women helps balance these hormones and, when used with a custom nutrition program, can provide relief for women across the U.S.
Sermorelin is a synthetic hormone peptide, like GHRH, which triggers the release of growth hormones. When used under the care of a qualified physician, Sermorelin can help you lose weight, increase your energy levels, and help you feel much younger.
Human growth hormone (HGH) therapy has been used for years to treat hormone deficiencies. Unlike HGH, which directly replaces declining human growth hormone levels, Sermorelin addresses the underlying cause of decreased HGH, stimulating the pituitary gland naturally. This approach keeps the mechanisms of growth hormone production active.
Ipamorelin helps to release growth hormones in a person's body by mimicking a peptide called ghrelin. Ghrelin is one of three hormones which work together to regulate the growth hormone levels released by the pituitary gland. Because Ipamorelin stimulates the body to produce growth hormone, your body won't stop its natural growth hormone production, which occurs with synthetic HGH.
Ipamorelin causes growth hormone secretion that resembles natural release patterns rather than being constantly elevated from HGH. Because ipamorelin stimulates the natural production of growth hormone, our patients can use this treatment long-term with fewer health risks.
One of the biggest benefits of Ipamorelin is that it provides significant short and long-term benefits in age management therapies. Ipamorelin can boost a patient's overall health, wellbeing, and outlook on life.
When growth hormone is produced by the pituitary gland using Ipamorelin, clients report amazing benefits. Some of those benefits include:
Whether you are considering our HRT and anti-aging treatments for women in Woodcliff Lake, NJ, we are here to help. The first step to reclaiming your life begins by contacting Global Life Rejuvenation. Our friendly, knowledgeable HRT experts can help answer your questions and walk you through our procedures. From there, we'll figure out which treatments are right for you. Before you know it, you'll be well on your way to looking and feeling better than you have in years!973-587-8638
Real Estate The Garden State’s commercial real estate community recognized the achievements of leading professionals and firms and the state’s most impactful transactions of 2022 as NAIOP New Jersey hosted its 35th Annual Commercial Real Estate Awards Gala recently at the Palace at Somerset Park.In his opening remarks, NAIOP NJ President Constantino T. “Gus” Milano, president and COO of Hartz Mountain Industries, said, “Our honorees truly represent the best of real estate and economic development. ...
The Garden State’s commercial real estate community recognized the achievements of leading professionals and firms and the state’s most impactful transactions of 2022 as NAIOP New Jersey hosted its 35th Annual Commercial Real Estate Awards Gala recently at the Palace at Somerset Park.
In his opening remarks, NAIOP NJ President Constantino T. “Gus” Milano, president and COO of Hartz Mountain Industries, said, “Our honorees truly represent the best of real estate and economic development. They’re inspired by a commitment to excellence in transforming New Jersey communities, and all of them will have a lasting, positive impact on our state and our industry.”
The Charles Klatskin Lifetime Achievement Award was presented to Gene Preston, who recently retired from Dermody Properties. Preston developed and acquired nearly 28 million square feet of industrial and logistics space representing approximately $2 billion of invested capital during his career. An active member of NAIOP for 33 years, he served as president of the New Jersey Chapter in 2019 and 2020.
David Gockel, president/CEO of Langan, and Onyx Equities, whose founders and managing principals are John Saraceno and Jonathan Schultz, accepted the Impact Award in recognition of their influence on the industrial and office development communities. Anthony Coscia, partner at Windels Marx Lane & Mittendorf LLP, was honored with the Industry Service Award in recognition of his considerable contributions in support of the industry’s goals.
The Caren S. Franzini Public Partner Award, which recognizes champions of economic development that inspire and transform communities, was presented to City of Linden Mayor Derek Armstead.
In addition to celebrating the achievements of leading commercial real estate professionals and firms, NAIOP NJ recognized the year’s most impactful real estate transactions. Deal of the Year winners in three categories – Industrial, Office and Mixed-Use – were chosen by a panel of judges based on impact on the community and marketplace; degree of complexity and/or uniqueness; innovative strategies; and creative problem solving.
Office Deal of the Year: Party City Headquarters Operations Lease, Woodcliff Lake. As the first-ever New Jersey Economic Development Authority Emerge Program recipient, Party City Holdings Inc. secured a 7-year, $9.996 million tax credit for its 208,911-square-foot Class A headquarters lease at 100 Tice Blvd. Involved in the deal: Party City, Cushman & Wakefield, Savills Studley, CBRE, Inc. and Gensler.
Industrial Deal of the Year: Target at Logan North, Logan Township. The team of Greek Development, Advance Realty Investors and CBRE successfully leased a 1.7-million-square-foot omnichannel flow center to Target Corp. The asset traded for a record-breaking $265 million when Torchlight Investors of New York bought the building in September 2021.
Mixed-Use Deal of the Year: HalRay Newark Portfolio, Newark. The HalRay Newark Portfolio is a three-building portfolio totaling approximately 800,000 square feet of office/retail space with a 901-space parking deck. The sponsors have planned approximately $40 million of capital improvements with the goal of driving further activity along the Halsey Corridor and throughout the city. Involved in the deal: Hanini Group, Shift Capital, Colnvestment Partners, Murphy Schiller & Wilkes LLP and JLL Capital Markets.
A special Transformation Award went to RCINJ Jack & Sheryl Morris Cancer Center, a partnership among New Brunswick Development Corporation (Devco), Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, Robert Wood Johnson University Hospital, Rutgers Biomedical & Health Sciences and Middlesex County that will bring New Brunswick the state’s first freestanding cancer hospital.
To access more business news, visit NJB News Now.
Margaret Qualley and Jack Antonoff answered headline speculation with photographic evidence.The couple, who were rumored to be engaged, confirmed their impending union with a series of pictures that prominently showcase Qualley’s ring as the actor embraces the musician.“Oh I love him!” Qualley said in her caption for the Instagram post Tues...
The couple, who were rumored to be engaged, confirmed their impending union with a series of pictures that prominently showcase Qualley’s ring as the actor embraces the musician.
“Oh I love him!” Qualley said in her caption for the Instagram post Tuesday, tagging her husband-to-be.
Antonoff, who wears a Whitney Houston shirt in the engagement selfies, grew up in New Milford and Woodcliff Lake.
Qualley, 27, and Antonoff, 38, were first linked last summer.
Antonoff, who performs as Bleachers, is a Grammy-winning producer and songwriter who has worked with artists like Taylor Swift, St. Vincent, Florence and the Machine and Lana Del Rey, winning the 2022 Grammy for producer of the year (non-classical). He was formerly a member of the band Fun.
Qualley also appeared in HBO’s “The Leftovers” and the films “Stars At Noon,” directed by Claire Denis, which just premiered at the Cannes Film Festival (where it won the Grand Prix) and Quentin Tarantino’s “Once Upon a Time... In Hollywood” (2019). She received her first Emmy nomination in 2019 for playing Ann Reinking in the FX miniseries “Fosse/Verdon” and was nominated for a Golden Globe for her lead role in “Maid.”
Antonoff was previously in a long-term relationship with Lena Dunham, the writer, director and actor who created the HBO series “Girls.” Dunham married musician Luis Felber in 2021.
Qualley previously dated Pete Davidson and Shia LeBeouf.
Thank you for relying on us to provide the journalism you can trust. Please consider supporting NJ.com with a subscription.
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- PowerFleet, Inc. (Nasdaq: PWFL), a global leader of SaaS-based data insight solutions that manage enterprise assets, enabling unification of their business operations, will virtually host its inaugural Investor Day on Tuesday, June 14, 2022 from 11:30 a.m. to 2:30 p.m. Eastern t...
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- PowerFleet, Inc. (Nasdaq: PWFL), a global leader of SaaS-based data insight solutions that manage enterprise assets, enabling unification of their business operations, will virtually host its inaugural Investor Day on Tuesday, June 14, 2022 from 11:30 a.m. to 2:30 p.m. Eastern time.
PowerFleet CEO Steve Towe will be joined by CTO Jim Zeitunian, CRO Patrick Maley and other senior executives to discuss the company’s enhanced vision, growth drivers, go-to-market strategy, software and AI roadmap, and target financial model. The event will include interactive Q&A and product demonstrations that highlight how global companies can unify their IoT data, manage macro-economic challenges such as rising fuel prices as well as leverage data science to drive more profitable business decisions.
About PowerFleetPowerFleet® Inc. (NASDAQ: PWFL; TASE: PWFL) is a global leader of subscription-based wireless solutions that manage enterprise assets for seamless business operations. PowerFleet’s patented technologies are the proven solution for organizations that must monitor and analyze their assets to improve safety, increase efficiency, reduce costs, and drive profitability. Our offerings are sold under the global brands PowerFleet, Pointer, and Cellocator. PowerFleet’s global headquarters are in Woodcliff Lake, New Jersey, with additional offices around the globe. For more information, please visit www.powerfleet.com, the content of which does not form a part of this press release.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements with respect to PowerFleet’s beliefs, plans, goals, objectives, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond PowerFleet’s control, and which may cause its actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. For example, forward-looking statements include statements regarding prospects for additional customers; potential contract values; market forecasts; projections of earnings, revenues, synergies, accretion, or other financial information; emerging new products; and plans, strategies, and objectives of management for future operations, including growing revenue, controlling operating costs, increasing production volumes, and expanding business with core customers. The risks and uncertainties referred to above include, but are not limited to, future economic and business conditions, the ability to recognize the anticipated benefits of the acquisition of Pointer, which may be affected by, among other things, the loss of key customers or reduction in the purchase of products by any such customers, the failure of the market for PowerFleet’s products to continue to develop, the possibility that PowerFleet may not be able to integrate successfully the business, operations and employees of I.D. Systems and Pointer, the inability to protect PowerFleet’s intellectual property, the inability to manage growth, the effects of competition from a variety of local, regional, national and other providers of wireless solutions, and other risks detailed from time to time in PowerFleet’s filings with the Securities and Exchange Commission, including PowerFleet’s annual report on Form 10-K for the year ended December 31, 2021. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PowerFleet. Unless otherwise required by applicable law, PowerFleet assumes no obligation to update the information contained in this press release, and expressly disclaims any obligation to do so, whether a result of new information, future events, or otherwise.
PowerFleet Media ContactCalen McGee[email protected](908) 461-0266
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter ---- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting ---- Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for prop...
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter --
-- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting --
-- Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for proposed pediatric study plans for a future FDA submission --
-- If landiolol is approved, Eagle expects five years of new chemical entity exclusivity --
WOODCLIFF LAKE, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group (“AOP Health”), with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for landiolol, a short-acting, intravenous (“IV”), cardio-selective beta-1 adrenergic blocker. The submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.
“The submission of the landiolol NDA is a significant step forward for our company, as we look to bring this important therapeutic candidate to the U.S. market and to expand our footprint in the acute care setting. We believe that landiolol has the potential to become a cornerstone therapy in the management of tachycardia in critically ill patients. Landiolol has differentiated clinical characteristics and an established safety profile, and we look forward to working with FDA during the course of the review process,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
“We are successfully diversifying our revenue stream, anticipated to grow from three commercial products just last year to eight upon the closing of the anticipated Acacia Pharma transaction, and nine with landiolol, if approved. We look forward to the potential of adding another strong product to our portfolio and to leveraging our highly capable hospital-based sales force,” concluded Tarriff.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin injection, PEMFEXY™, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at .
Lisa M. WilsonIn-Site Communications, Inc. T: 212-452-2793 E:
Party City Holdings Inc. is relocating its global headquarters to a Woodcliff Lake office building beginning in 2022, according to a Thursday announcement from Signature Acquisitions.The largest retailer of party goods in North America signed a full-building lease at 100 Tice Blvd., a 208,911-square-foot Class A office building.Ben Brenner of ...
The largest retailer of party goods in North America signed a full-building lease at 100 Tice Blvd., a 208,911-square-foot Class A office building.
Ben Brenner of Cushman & Wakefield and Harlan Hollander of Savills represented Party City, and Joe Sarno Sr., Jon Meisel and Jeff Babikian of CBRE represented Signature Acquisitions in the transaction.
Originally founded in East Hanover, the company’s headquarters operations were spread across two offices, in Rockaway and Elmsford, New York. In September, the company said it was seeking to consolidate its headquarters operations, and Woodcliff Lake and the surrounding Upper Parkway submarket’s strong underlying fundamentals made it stand out among competing areas in the region.
The Fortune 100 company was the first to win an award under the Emerge program, the new job creation incentive touted by Gov. Phil Murphy and created under the New Jersey Economic Recovery Act of 2020. It will be bringing its headquarters — and 357 new jobs — to Bergen County, in accordance with a seven-year award for just under $10 million ($9,996,000) that was approved by the board of the New Jersey Economic Development Authority.
Conveniently located less than one mile from the Garden State Parkway and five miles from Interstates 87 and 287 in the borough of Woodcliff Lake, the asset is a three-story building that was acquired by Signature Acquisitions in 2019. Party City recognized that the building’s superior connectivity to regional transportation networks, its strong local demographics and its adaptability made it an ideal future headquarters location.
The building’s proximity to the New Jersey-New York border provides the company’s current employees with added convenience and accessibility while expanding its reach to attract additional top talent. Party City will take advantage of the EDA’s Emerge program award to fund major capital improvements at the building that will create a collaborative workplace geared to the needs of the growing company and its employee base.
“Our focus on acquiring best-in-class suburban office spaces and maintaining them to the highest standards has consistently created one-of-a-kind corporate destinations geared towards the needs of companies today,” said Rich Travaglini, senior vice president/director of leasing for Signature Acquisitions. “Party City’s return to New Jersey exemplifies our portfolio’s continued deep appeal to a wide range of companies hoping to tap into all that makes the tri-state area unique.
“We welcome Party City back to Garden State and we look forward to working with them to create a dynamic workplace that will foster the collaboration and creativity necessary for continued growth.”